Revvity | Sustainability Performance
A company providing solutions in diagnostics and life sciences.
1937
United States
10,001+ employees
Biotechnology
$1B - 10B in revenue
$100M - 500M in profitability
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#1242
Overallⓘ#271
in United Statesⓘ#17
in BiotechnologyⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Environmental
Carbon emissionsEnergy consumptionWaste ManagementWater ManagementNature and biodiversitySocial
Diversity and InclusionPay GapsHealth and SafetyExternalitiesGovernance
SDG ImpactFinancial Data
Business performanceCapital & innovationAnalyst projections
Aligned
Aligned
Aligned
Critical
Aligned
Intensity
Greenhouse gas intensity Scope 1, 2 (tCO₂e /$M)
Energy consumption (direct) intensity (MWh /$M)
Water consumption intensity (m³ /$M)
Industry Benchmark
10.3
B/M 10.8
34.4
B/M 27.9
97.0
B/M 102.0
Powered by illuminem and GIST Impact
Controversy level
- Revvity Inc (formerly PerkinElmer Discovery + Diagnostics rebrand 2023), US life sciences, has faced multiple US shareholder class actions over the contested 2023 USD 2.45 billion PerkinElmer applied/laboratory services divestiture to New Mountain Capital affecting institutional shareholders, plus periodic US FDA enforcement at multiple Revvity diagnostics production facilities.
Sustainability employees
ⓘWe follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.Total sustainability employees
11+
ⓘThis value represents the estimated number of employees in a company with sustainability-related roles or job titles, as determined by Illuminem using publicly available data.